23003-35-2

Basic information

• Product Name: 2-Bromo-3-hydroxy-6-methylpyridine
• Synonyms: 2-BROMO-6-METHYL-3-PYRIDINOL;2-BROMO-3-HYDROXY-6-PICOLINE;2-Bromo-3-hydroxy-6-methylpyridine;2-Bromo-6-methyl-3-pyridinol ,97%;2-Bromo-6-methylpyridin-3-ol, 6-Bromo-5-hydroxy-2-picoline;2-BROMO-6-METHYLPYRIDIN-3-OL
• CAS NO: 23003-35-2
• Molecular Formula: C₆H₆BrNO
• Molecular Weight: 188.02
• Product Categories: Pyridine
• Mol File: 23003-35-2.mol
• Article Data: 22

Chemical Properties

• Melting Point: 186-187 °C
• Boiling Point: 311.781 °C at 760 mmHg
• Flash Point: 142.361 °C
• Appearance: /
• Density: 1.656 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.598
• Storage Temp.: Inert atmosphere,Room Temperature
• PKA: 4.66±0.10(Predicted)
• CAS DataBase Reference: 2-Bromo-3-hydroxy-6-methylpyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Bromo-3-hydroxy-6-methylpyridine(23003-35-2)
• EPA Substance Registry System: 2-Bromo-3-hydroxy-6-methylpyridine(23003-35-2)

Safety Data

• Statements: 36/37/38
• Safety Statements: 24/25
• Hazardous Substances Data: 23003-35-2(Hazardous Substances Data)

Usage

Chemical Properties

White solid

Synthesis Reference(s)

Tetrahedron, 61, p. 4569, 2005 DOI: 10.1016/j.tet.2005.03.008

InChI:InChI=1/C6H6BrNO/c1-4-2-3-5(9)6(7)8-4/h2-3,9H,1H3

Upstream product

• 1121-78-4 5-Hydroxy-2-methylpyridine 
• 109-72-8 n-butyllithium 
• 23003-29-4 2,4-dibromo-3-hydroxy-6-methylpyridine 
• 594-19-4 tert.-butyl lithium 
• 920-36-5 (2-methylpropyl)lithium 

Downstream Products

• 24207-22-5 2-bromo-3-methoxy-6-methyl-pyridine 
• 54232-43-8 6-bromo-5-methoxy-2-pyridinecarboxylic acid 
• 170235-19-5 methyl 2-bromo-3-hydroxy-6-pyridinecarboxylate 
• 170235-18-4 methyl 2-bromo-3-methoxy-6-pyridinecarboxylic acid 
• 178876-92-1 6-Bromo-5-hydroxy-pyridine-2-carboxylic acid 
• 168015-04-1 2-bromo-6-(hydroxymethyl)pyridin-3-ol 
• 1342891-22-8 N-((8-bromo-2,2-dimethyl-2H-pyrano[2,3-c]pyridin-6-yl)-methyl)benzenamine 
• 1342891-24-0 N-((2,2-dimethyl-2H-pyrano[2,3-c]pyridin-6-yl)methyl)benzenamine 
• 1342891-05-7 N-((2,2-dimethyl-2H-pyrano[2,3-c]pyridin-6-yl)methyl)-4-methoxy-N-phenylbenzenesulfonamide 
• 1342891-23-9 N-((8-bromo-2,2-dimethyl-2H-pyrano[2,3-c]pyridin-6-yl)-methyl)cyclohexanamine 
• 1342891-25-1 N-((2,2-dimethyl-2H-pyrano[2,3-c]pyridin-6-yl)methyl)-cyclohexanamine 
• 1342891-06-8 N-((2,2-dimethyl-2H-pyrano[2,3-c]pyridin-6-yl)methyl)-4-nitro-N-phenylbenzenesulfonamide 
• 1342891-07-9 N-cyclohexyl-N-((2,2-dimethyl-2H-pyrano[2,3-c]pyridin-6-yl)methyl)-4-isopropylbenzenesulfonamide 
• 1342891-08-0 N-cyclohexyl-N-((2,2-dimethyl-2H-pyrano[2,3-c]pyridin-6-yl)methyl)-3,4-dimethoxybenzenesulfonamide 

Relevant articles and documents

Metal-ion sensing europium(III) complexes with bidentate phosphine oxide ligands containing a 2,2′-bipyridine framework

Novel EuIII complexes with bidentate phosphine oxide ligands containing a bipyridine framework, i.e., [3,3′-bis(diphenylphosphoryl)-2, 2′-bipyridine]tris(hexafluoroacetylacetonato)europium(III) ([Eu-(hfa) 3(BIPYPO)]) and [3,3′-bis(diphenylphosphoryl)-6,6′- dimethyl-2,2′-bipyridine]tris(hexafluoroacetylacetonato)europium(III) ([Eu(hfa)3(Me-BIPYPO)]), were synthesized for lanthanide-based sensor materials having high emission quantum yields and effective chemosensing properties. The emission quantum yields of [Eu(hfa)3(BIPYPO)] and [Eu(hfa)3(Me-BIPYPO)] were 71 and 73%, respectively. Metal-ion sensing properties of the EuIII complexes were also studied by measuring the emission spectra of EuIII complexes in the presence of ZnII or CuII ions. The metal-ion sensing and the photophysical properties of luminescent EuIII complexes with a bidentate phosphine oxide containing 2,2′-bipyridine framework are demonstrated for the first time.

ROR-GAMMA INHIBITORS

The present invention relates to compounds of formula I and pharmaceutical compositions comprising compounds of formula I. Compounds of Formula I are useful in treatment of inflammatory, metabolic or autoimmune diseases which are mediated by RORy.

COMPOSITIONS AND USES OF AMIDINE DERIVATIVES

Use of a compound of formula (I): wherein A, X, Y, R1 and R2 as defined herein, in treating hereditary angioedema is disclosed. A composition containing the compounds, a polar organic solvent or a mixture thereof; and optionally a co-solvent, is also disclosed.